Zortix
Sign in
What the podcasts are saying about
STVN
In-depth coverage
0
Mentions · 7d
0
Mentions · 30d
7
Mentions · 90d
1
Episodes
Latest attributed ideas · most recent first
5 MAY5 MAYYET ANOTHER VALUE PODCAST · 15:00
GLP-1 oral threat overblown for Stevanato
“The bull case argued that the market's fear of GLP-1 injectables losing share to oral versions is an overreaction, as injectables remain more effective and necessary for severe cases, and the overall GLP-1 market is still in early growth.”
Core thesis · 5/5Verify in source →
5 MAY5 MAYYET ANOTHER VALUE PODCAST · 03:30
FDA 'spec-in' creates durable regulatory moat
“The guest explained that Stevanato's business model benefits from a powerful regulatory lock-in, where drug developers must specify a containment/delivery system early in the R&D process and cannot easily switch suppliers.”
In depth · 4/5Verify in source →
5 MAY5 MAYYET ANOTHER VALUE PODCAST · 00:45
GLP-1 overhang crushed Stevanato's valuation
“The guest argued the market's reaction to GLP-1 drug capacity concerns has been excessive, creating a potential opportunity as the stock price decline far outweighs the plausible revenue impact.”
In depth · 4/5Verify in source →
5 MAY5 MAYYET ANOTHER VALUE PODCAST · 10:00
Margin expansion from biologics shift
“The thesis presented was that Stevanato's revenue mix is shifting towards higher-margin, pre-sterilized 'High-Value Solutions' for biologics, driving significant EBITDA margin expansion without needing cost cuts.”
In depth · 4/5Verify in source →
5 MAY5 MAYYET ANOTHER VALUE PODCAST · 11:30
Capex cycle turning to free cash flow
“The case made was that Stevanato's heavy recent capital expenditure cycle is ending, which will convert a larger portion of its EBITDA into free cash flow, improving valuation metrics.”
Substantive discussion · 3/5Verify in source →
5 MAY5 MAYYET ANOTHER VALUE PODCAST · 06:50
Future capital allocation: buybacks and bolt-on M&A
“The guest projected that as Stevanato's major capacity expansion capex winds down, free cash flow will be allocated to a mix of share buybacks and strategic, bolt-on acquisitions.”
Substantive discussion · 3/5Verify in source →
5 MAY5 MAYYET ANOTHER VALUE PODCAST · 12:30
Stevanato as a fine compounder, not a value play
“The host concluded that while he likes Stevanato's business, it lacks the 'distress' or 'event' angle he typically seeks, framing it instead as a 'fine compounder' or 'Excel spreadsheet type business'.”
Notable comment · 2/5Verify in source →
The weekly signal

Get a weekly digest of what podcasts said about your watchlist.

Pick a few tickers. Once a week we send the most-discussed ideas across finance podcasts, attributed and linked so you can verify. No noise, no advice.

Double opt-in: we’ll email you to confirm before anything else. We store your email and chosen tickers only to send this digest. Nothing else, and we never share them.

Related tickers
GOOGLMSFTNVDAMETAAAPLAMZNMUTSLABTCORCLINTCSPY
Browse all tickers →This week’s signal →
MENTIONS & DEPTH REFLECT PODCAST DISCUSSION VOLUME · NOT A RATING, FORECAST, OR RECOMMENDATION